Ilyang, Daewoong sign deal to sell Supect

Published: 2012-10-23 06:59:00

Updated: 2012-10-23 06:59:00

Ilyang Pharmaceutical Co. said Friday it established a strategic partnership with Daewoong Pharmaceutical Co. to sell Supect, a newly-developed drug for myelogenous leukemia by Ilyang, in Korea.

Under the deal, Ilyang will devote itself to carry out Phase 3 clinical trial of Supect, while Daew...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK